Medicare Enrolled
Dr. Hosam Saad-Naguib, MD
Hematology & Oncology · Dalton, GA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Saad-Naguib from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Saad-Naguib?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Saad-Naguib
Dr. Hosam Saad-Naguib is a hematology & oncology specialist in Dalton, GA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Saad-Naguib performed 99,774 Medicare services across 2,621 unique beneficiaries.
Between the years covered by Open Payments, Dr. Saad-Naguib received a total of $4,242 from 50 pharmaceutical and/or device companies across 262 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Saad-Naguib is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 9% volume in GA
$4,242 industry payments
Medicare Practice Summary
Medicare Utilization ↗99,774
Medicare services
Top 9% in GA for hematology & oncology
2,621
Unique beneficiaries
$10
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~4,989 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
63,750 | $1 | $2 |
| Pembrolizumab injection (Keytruda) | 14,200 | $43 | $69 |
| Darbepoetin injection (Aranesp) for anemia An injection of darbepoetin alfa used for non-end-stage renal disease purposes. |
7,950 | $2 | $4 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
3,401 | $8 | $14 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
2,878 | $0 | $1 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
2,833 | $8 | $15 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
898 | $89 | $201 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
441 | $10 | $67 |
| Office visit for established patient An office visit for an existing patient that may not require the healthcare professional to be present. |
391 | $17 | $36 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
363 | $91 | $376 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
348 | $1 | $3 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
320 | $130 | $281 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
292 | $20 | $85 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
168 | $60 | $144 |
| Venipuncture for blood collection A procedure to draw blood from a vein for medical testing or analysis. |
157 | $65 | $244 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
130 | $44 | $186 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
117 | $19 | $83 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
113 | $11 | $65 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
109 | $90 | $188 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 107 | $356 | $581 |
| Enhanced Oncology Model monthly payment This code represents the monthly enhanced oncology services payment under the Enhancing Oncology Model. It covers the administrative payment for enhanced services provided to eligible patients. |
104 | $73 | $70 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
85 | $7 | $12 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
80 | $1 | $2 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
67 | $46 | $186 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
67 | $18 | $74 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
63 | $2 | $4 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
61 | $9 | $38 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
61 | $60 | $125 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
55 | $23 | $163 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
50 | $39 | $90 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
42 | $105 | $262 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
32 | $38 | $78 |
| New patient office visit, complex (60-74 min) | 16 | $165 | $342 |
| Comprehensive metabolic blood panel A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers. |
14 | $10 | $18 |
| Stool test for blood A laboratory test that checks a stool sample for hidden blood using a chemical reaction. This test helps detect bleeding in the digestive tract. |
11 | $4 | $8 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
64.9% high complexity
26.4% medium
8.8% routine
Industry Payment Transparency
Open Payments through 2024 ↗$4,242
Total received (2018-2024)
Avg $606/year across 7 years
Top 47% in GA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
50
Companies
262
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$3,699 (87.2%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$543 (12.8%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$195
2023
$248
2022
$564
2021
$1,029
2020
$709
2019
$829
2018
$667
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
TerSera Therapeutics LLC
$35
Novartis Pharmaceuticals Corporation
$27
Daiichi Sankyo Inc.
$27
ABBVIE INC.
$25
Astellas Pharma US Inc
$25
Eisai Inc.
$22
Merck Sharp & Dohme LLC
$18
Regeneron Healthcare Solutions, Inc.
$17
Top 3 companies account for 45.4% of 2024 payments
All-time payments by company (2018-2024) ›
PFIZER INC.
$442
E.R. Squibb & Sons, L.L.C.
$321
AstraZeneca Pharmaceuticals LP
$249
Merck Sharp & Dohme Corporation
$228
Novartis Pharmaceuticals Corporation
$195
Seagen Inc.
$192
Amgen Inc.
$181
Astellas Pharma US Inc
$171
Genentech USA, Inc.
$165
Seattle Genetics, Inc.
$149
Celgene Corporation
$143
Exelixis Inc.
$141
Incyte Corporation
$130
Pharmacyclics LLC, An AbbVie Company
$119
Eisai Inc.
$101
Daiichi Sankyo Inc.
$100
Gilead Sciences, Inc.
$92
GlaxoSmithKline, LLC.
$77
Janssen Biotech, Inc.
$74
Alexion Pharmaceuticals, Inc.
$73
Pfizer Inc.
$72
Rigel Pharmaceuticals, Inc.
$60
TerSera Therapeutics LLC
$59
Merck Sharp & Dohme LLC
$54
Regeneron Healthcare Solutions, Inc.
$52
ABBVIE INC.
$50
Bayer HealthCare Pharmaceuticals Inc.
$43
ARRAY BIOPHARMA INC
$38
Boehringer Ingelheim Pharmaceuticals, Inc.
$37
Verastem, Inc.
$34
Epizyme, Inc.,
$32
Heron Therapeutics, Inc.
$32
MACROGENICS, INC.
$29
BeiGene USA, Inc.
$28
AMAG Pharmaceuticals, Inc.
$27
Pharmacyclics LLC, an AbbVie Company
$24
JAZZ PHARMACEUTICALS INC.
$23
TG Therapeutics, Inc.
$20
PUMA BIOTECHNOLOGY, INC.
$20
Myovant Sciences Inc.
$20
Ipsen Biopharmaceuticals, Inc
$18
Karyopharm Therapeutics Inc.
$18
Lexicon Pharmaceuticals, Inc.
$16
Myriad Genetic Laboratories, Inc.
$15
TESARO, Inc.
$14
GENZYME CORPORATION
$14
Agios Pharmaceuticals, Inc.
$13
Dova Pharmaceuticals
$12
AbbVie Inc.
$12
Kite Pharma, Inc.
$11
Top 3 companies account for 23.9% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · Abraxane · Alecensa · Avastin · BAVENCIO · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Blincyto · CABOMETYX · CALQUENCE · CINVANTI · Cabometyx · Cinvanti · Copiktra · DALVANCE · Doptelet · EMPLICITI · EPKINLY · Enhertu · FERAHEME · GILOTRIF · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Imbruvica · JAKAFI · KEYTRUDA · KISQALI · Kyprolis · LENVIMA · LIBTAYO · LYNPARZA · Lenvima · MARGENZA · MEKINIST · MVASI · NERLYNX · Neulasta · OPDIVO · ORGOVYX · PADCEV · PROMACTA · Padcev · Phesgo · Pomalyst · REBLOZYL · Revlimid · SOLIRIS · SOMATULINE DEPOT · Stivarga · TAGRISSO · TALZENNA · TASIGNA · TAZVERIK · TECENTRIQ · TIBSOVO · TUKYSA · Tavalisse · Trodelvy · UKONIQ · ULTOMIRIS · Ultomiris · VENCLEXTA · XALKORI · XPOVIO · XTANDI · Xermelo · ZEJULA · ZEPZELCA · Zoladex · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (87%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
12
Per 100K population
11.6
County median income
$64,262
Nearest hospital
HAMILTON MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Saad-Naguib is a mixed practice specialist, with above-average Medicare volume (top 9% in GA), with low-engagement industry engagement, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Saad-Naguib experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Saad-Naguib performed 63,750 iron infusion (injectafer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Saad-Naguib receive payments from pharmaceutical companies?
Yes. Dr. Saad-Naguib received a total of $4,242 from 50 companies across 262 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Saad-Naguib's costs compare to other hematology & oncology specialists in Dalton?
Dr. Saad-Naguib's average Medicare payment per service is $10. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Saad-Naguib) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Dalton
Browse hematology & oncology specialists in Dalton ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in GA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in GA
Which GA hematology & oncology specialists receive the most from drug and device companies.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology